We thank Burucoa et al. for their comments and concerns regarding the association of the T2182C mutation and clarithromycin resistance in H. pylori. The frequency of isolates resistant to a given drug varies geographically, but most clarithromycin resistance in H. pylori from the United States, Europe, and East Asia has been shown to be associated with point mutations, generally A to G or C at position 2142 or 2143 of the 23S rRNA gene (1, 5, 13, 14). Resistance due to mutations at other positions of the 23S rRNA gene, e.g., A2115G, G2141A, T2182C, G2224A, C2245T, T2289C, and T2717C (2, 4, 5, 6, 7), and resistance without mutations in the 23S rRNA have also been reported (2, 12, 15). In H. pylori, resistance to clarithromycin may be low or high level, and the molecular mechanism of low- and high-level resistance is poorly understood. However, a mutation at position 2143 is usually associated with different levels of resistance, with MICs ranging from ≤0.016 to ≥256 μg/ml, while MICs of strains with a mutation at position 2142 frequently were ≥64 μg/ml (3, 15). Mutations at other positions or no mutation in the 23S rRNA has also been associated with different levels of Clar.
We would like to respond to points raised by Burucoa et al. The association of the T2182C mutation and Clar was first reported by Kim et al. (7), and in our study we confirmed the earlier finding by transformation and sequencing of 23S rRNA from single-colony isolates. It is apparent from the letter that Burucoa et al. performed all of their initial analysis (isolation, MIC determination, DNA extraction, PCR, sequencing, and transformation) with pooled isolates and subsequently realized that they were working with mixed isolates. It seems that they used only the E-test for MIC determination, and in our experience the determination of the MIC for low-level clarithromycin-resistant H. pylori needs careful reading of E-test results and confirmation by the agar dilution method. It is not clear a t which concentration of clarithromycin they selected the transformants, and it seems that they did not confirm the 23S rRNA gene of the transformants by DNA sequencing. In most standard laboratories, the MIC determination is usually done several times to confirm the reproducibility of the result, and it is not clear whether Burucoa et al. got small and big colonies each time or only the last time. When they cultured the frozen biopsy sample, they identified 52 sensitive colonies and only one resistant colony. It might be important to analyze the 23S rRNA gene sequences of the sensitive and resistant isolates fo r confirmation of their finding. However, it was also not clear whether they indicated that they found the T2182C mutation in both copies of the 23S rRNA gene of their sensitive isolates.
Many laboratories, including ours, store H. pylori isolates as a pool and as propagation from a single colony, which is standard procedure for storage of H. pylori in order to avoid confusions of mixed infection. Burucoa et al. worked with only one high-level Clar isolate (they initially worked with mixed isolates and subsequently realized that fact but have not shown any data on the isolates from the frozen biopsy sample), and it might be difficult to come to a definite conclusion based on the results from one isolate. In contrast, we worked with 12 individual, pretreatment Clar isolates, and the MICs of clarithromycin for the isolates were determined by both the agar dilution and the E-test methods at least twice in every step where the results were reproducible. Finally, we confirmed the association of the T2182C mutation by transformation and DNA sequencing. It should be noted that our strains exhibit only low levels of Clar (MIC, 1 to 4 μg/ml) and that the T2182C mutation was absent in the sensitive strains tested (n = 3) (MIC, ≤0.016 to 0.5 μg/ml). Burucoa et al. rightly mentioned the error rate of Taq polymerase, but it is unusual to get the error each time at the same position.
We agree that some authors have shown that the T2182C mutation has no role in clarithromycin resistance (8, 16), at least in the isolates tested. This fact is not surprising because it is known that the genetic character of H. pylori in different areas is different (10, 11, 17), as are the genetic characters of resistant H. pylori strains (9). The following reasons are several possible explanations for the T2182C mutation and clarithromycin resistance among H. pylori isolates in Bangladesh. (i) The use of macrolides in this society became widespread only recently (since the late 1990s), and incomplete therapy is common. Under these circumstances, T2182C may represent a transient state, a relative hotspot for mutation, and might be subject to replacement later on by alleles that confer higher-level resistance (e.g., changes at position 2142 or 2143). (ii) The predominance of duodenal ulcer disease in South Asia, in contrast to gastric ulcer disease in other societies, might offer a selective advantage to the T2182C allele or be less costly than other resistance alleles in the usual Bangladeshi gastric environments. (iii) Differences in predominant genotypes of South Asian H. pylori strains from those from Europe, East Asia, and the Americas might favor T2182C or be more effective in conferring resistance due to its interaction with other ribosomal protein components or rRNA motifs.
REFERENCES
-
1.Alarcon, T., D. Domingo, N. Prieto, and M. Lopez-Brea. 2000. Clarithromycin resistance stability in Helicobacter pylori: influence of the MIC and type of mutation in the 23S rRNA. J. Antimicrob. Chemother. 46:613-616. [DOI] [PubMed] [Google Scholar]
-
2.Fontana, C., M. Favaro, S. Minelli, A. A. Criscuolo, A. Pietroiusti, A. Galante, and C. Favalli. 2002. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob. Agents Chemother. 46:3765-3769. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
3.Garcia-Arata, M. I., F. Baquero, L. de Rafael, C. Martin de Argila, J. P. Gisbert, F. Bermejo, D. Boixeda, and R. Canton. 1999. Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. Antimicrob. Agents Chemother. 43:374-376. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
4.Hao, Q., Y. Li, Z. J. Zhang, Y. Liu, and H. Gao. 2004. New mutation points in 23S rRNA gene associated with Helicobacter pylori resistance to clarithromycin in northeast China. World J. Gastroenterol. 10:1075-1077. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
5.Hulten, K., A. Gibreel, O. Skold, and L. Engstrand. 1997. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob. Agents Chemother. 41:2550-2553. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
6.Khan, R., S. Nahar, J. Sultana, M. M. Ahmad, and M. Rahman. 2004. T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh. Antimicrob. Agents Chemother. 48:3567-3569. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
7.Kim, K. S., J. O. Kang, C. S. Eun, D. S. Han, and T. Y. Choi. 2002. Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance. J. Korean Med. Sci. 17:599-603. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
8.Matsuoka, M., Y. Yoshida, K. Hayakawa, S. Fukuchi, and K. Sugano. 1999. Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure. Gut 45:503-507. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
9.Meyer, J. M., N. P. Silliman, W. Wang, N. Y. Siepman, J. E. Sugg, D. Morris, J. Zhang, H. Bhattacharyya, E. C. King, and R. J. Hopkins. 2002. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann. Intern. Med. 136:13-24. [DOI] [PubMed] [Google Scholar]
-
10.Mukhopadhyay, A. K., D. Kersulyte, J. Y. Jeony, S. Datta, Y. Ito, A. Chowdhury, S. Chowdhury, A. Santra, S. K. Bhattacharya, T. Azuma, G. B. Nair, and D. E. Berg. 2000. Distinctiveness of genotypes of Helicobacter pylori in Calcutta, India. J. Bacteriol. 182:3219-3227. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
11.Rahman, M., A. K. Mukhopadhyay, S. Nahar, S. Datta, M. M. Ahmad, S. Sarker, I. M. Masud, L. Engstrand, M. J. Albert, G. B. Nair, and D. E. Berg. 2003. DNA-level characterization of Helicobacter pylori strains from patients with overt disease and with benign infections in Bangladesh. J. Clin. Microbiol. 41:2008-2014. (Erratum, 41:3465.) [DOI] [PMC free article] [PubMed] [Google Scholar]
-
12.Ribeiro, M. L., L. Vitiello, M. C. Miranda, Y. H. Benvengo, A. P. Godoy, S. Mendonca, and J. Pedrazzoli, Jr. 2003. Mutations in the 23S rRNA gene are associated with clarithromycin resistance in Helicobacter pylori isolates in Brazil. Ann. Clin. Microbiol. Antimicrob. 2:11. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
13.Taylor, D. E., Z. Ge, D. Purych, T. Lo, and K. Hiratsuka. 1997. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agents Chemother. 41:2621-2628. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
14.Versalovic, J., D. Shortridge, K. Kimbler, M. V. Griffy, J. Beyer, R. K. Flamm, S. K. Tanaka, D. Y. Graham, and M. F. Go. 1996. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 40:477-480. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
15.Versalovic, J., M. S. Osato, K. Spakovsky, M. P. Dore, R. Reddy, G. G. Stone, D. Shortridge, R. K. Flamm, S. K. Tanaka, and D. Y. Graham. 1997. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. Antimicrob. Agents Chemother. 40:283-286. [DOI] [PubMed] [Google Scholar]
-
16.Wang, G., and D. E. Taylor. 1998. Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob. Agents Chemother. 42:1952-1958. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
17.Yamaoka, Y., M. S. Osato, A. R. Sepulveda, O. Gutierrez, N. Figura, J. G. Kim, T. Kodama, K. Kashima, and D. Y. Graham. 2000. Molecular epide-miology of Helicobacter pylori: separation of H. pylori from East Asian and non-Asian countries. Epidemiol. Infect. 124:91-96. [DOI] [PMC free article] [PubMed] [Google Scholar]